SUPERBUG NEWS: Is this the next Robinhood target?
“Don’t get ready, don’t aim – just fire.” Sal the Robinhood Trader lmao.
iBio currently anticipates that data from the preclinical immunization studies of its two COVID-19 vaccine candidates, IBIO-200 and IBIO-201, which are being conducted at Texas A&M University System laboratories, will be available in Q3-2020.
On March 11, 2020, the Company filed four provisional patent applications with the U.S. Patent and Trademark Office in support of its COVID-19 vaccine platforms. The virus-like particle (“VLP”) program (“IBIO-200”) was subsequently announced on March 18, 2020. The LicKM-Subunit program (“IBIO-201”) was announced on June 3, 2020.
If the program(s) move into clinical trials, iBio has the capability to rapidly develop and manufacture at clinical and commercial scales in its 130,000 square foot facility in Bryan, Texas. Originally built in 2010 with funding from the U.S. Defense Advanced Research Projects Agency (DARPA), iBio’s FastPharming FacilityTM was part of the “Blue Angel” initiative to establish factories capable of rapid delivery of medical countermeasures in response to a disease pandemic.
Follow CoronaMania stocks on our SuperBug News section.
Disclaimer, “What, are you nuts playing these stocks?”
(Not a client)